Skip to main content
Top
Published in: Endocrine Pathology 2/2015

01-05-2015

In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications

Authors: Zhenying Guo, Heather Hardin, Celina Montemayor-Garcia, Sofia Asioli, Alberto Righi, Francesca Maletta, Anna Sapino, Ricardo V. Lloyd

Published in: Endocrine Pathology | Issue 2/2015

Login to get access

Abstract

Some thyroid nodules such as follicular adenomas (FAs), follicular variant of papillary thyroid carcinomas (FVPTCs), and follicular thyroid carcinomas (FTCs) exhibit similar clinical presentations and gross morphologic appearances. The differential diagnosis of these lesions is sometimes difficult based on morphologic, cytologic, or clinical features alone. miR-146b-5p and miR-21 deregulation has been associated with progression and metastasis of thyroid cancers. However, the utility of in situ hybridization (ISH) to determine the cellular localization, diagnostic, and prognostic significance of miR-146b-5p and miR-21 expression in thyroid tumors has not been extensively analyzed. In order to examine the expression of miR-146b-5p and miR-21 in benign and malignant thyroid tissues and to determine if these microRNAs could be assigned to distinct histomorphological types of thyroid nodules, we analyzed miR-146b-5p and miR-21 expression in thyroid nodules on tissue microarrays (TMAs) with 193 thyroid specimens by ISH. miR-146b-5p and miR-21 expression in thyroid tissues was also analyzed by quantitative reverse transcription–polymerase chain reaction (qRT-PCR). miR-146b-5p was highly expressed (89 %) in papillary thyroid carcinomas (PTCs) and 41 % of FVPTC. The expression of miR-146b-5p was not expressed in most FTCs, anaplastic thyroid carcinomas (ATCs), poorly differentiated thyroid carcinomas (PDTCs), or FAs (7, 8, 0, and 0 %, respectively). MiR-21 was overexpressed in 83 % of ATCs, 79 % of PTCs, 34 % of FVPTCs, and 19 % of PDTCs. The expression of miR-21 was not expressed in most FAs (9 %) or FTCs (4 %). Normal thyroid tissues and most benign goiters were negative for miR-146b-5p and miR-21. qRT-PCR analysis supported the ISH findings. PTC cases with positive expression of miR-146b-5p and miR-21 had significantly poorer disease-free survival rates. Immunohistochemical staining for HBME-1 showed positive staining in PTCs (100 %) and FVPTCs (92 %) with a subset of FTC (40 %) staining positive, while all FAs were negative. Since miR-146b-5p was mainly expressed in PTC including FVPTC and was not expressed in most FTC, PDTC, or ATC, it may serve as a useful diagnostic marker for PTC. ISH is a useful method to analyze microRNA expression in formalin-fixed paraffin-embedded thyroid tissues.
Literature
2.
3.
go back to reference Gao Y, Wang C, Shan Z, Guan H, Mao J, Fan C, et al. miRNA expression in a human papillary thyroid carcinoma cell line varies with invasiveness. Endocr J 57:81–6, 2010.CrossRefPubMed Gao Y, Wang C, Shan Z, Guan H, Mao J, Fan C, et al. miRNA expression in a human papillary thyroid carcinoma cell line varies with invasiveness. Endocr J 57:81–6, 2010.CrossRefPubMed
4.
go back to reference Menon MP, Khan A. Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications. J Clin Pathol 62:978–85, 2009.CrossRefPubMed Menon MP, Khan A. Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications. J Clin Pathol 62:978–85, 2009.CrossRefPubMed
5.
go back to reference Nikiforova MN, Chiosea SI, Nikiforov YE. MicroRNA expression profiles in thyroid tumors. Endocr Pathol 20:85–91, 2009.CrossRefPubMed Nikiforova MN, Chiosea SI, Nikiforov YE. MicroRNA expression profiles in thyroid tumors. Endocr Pathol 20:85–91, 2009.CrossRefPubMed
6.
go back to reference Chou CK, Yang KD, Chou FF, et al. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab 98:E196-205, 2013.CrossRefPubMed Chou CK, Yang KD, Chou FF, et al. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab 98:E196-205, 2013.CrossRefPubMed
7.
go back to reference Dettmer M, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN. Comprehensive microRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid. 23:1383–1389, 2013.CrossRefPubMedCentralPubMed Dettmer M, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN. Comprehensive microRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid. 23:1383–1389, 2013.CrossRefPubMedCentralPubMed
8.
go back to reference Frezzetti D, De Menna M, Zoppoli P, Guerra C, Ferraro A et al. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 30:275–286, 2011.CrossRefPubMed Frezzetti D, De Menna M, Zoppoli P, Guerra C, Ferraro A et al. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 30:275–286, 2011.CrossRefPubMed
9.
go back to reference He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U SA 102:19075–19080, 2005.CrossRef He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U SA 102:19075–19080, 2005.CrossRef
10.
go back to reference Nikiforova MN, Tseng GC, Steward D, Diorio D & Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 93: 1600–1608, 2008.CrossRefPubMedCentralPubMed Nikiforova MN, Tseng GC, Steward D, Diorio D & Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 93: 1600–1608, 2008.CrossRefPubMedCentralPubMed
11.
go back to reference Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res 18: 2032–2038, 2012.CrossRefPubMed Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res 18: 2032–2038, 2012.CrossRefPubMed
12.
go back to reference Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn et al. Science 309:310–311, 2005.CrossRefPubMed Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn et al. Science 309:310–311, 2005.CrossRefPubMed
13.
go back to reference Ruebel K, Leontovich AA, Stilling GA, Zhang S, Righi A, Jin L, et al. MicroRNA expression in ileal carinoid tumors: downregulation of microRNA-133a with tumor progression. Mod Pathol 23:367–375, 2010.CrossRefPubMedCentralPubMed Ruebel K, Leontovich AA, Stilling GA, Zhang S, Righi A, Jin L, et al. MicroRNA expression in ileal carinoid tumors: downregulation of microRNA-133a with tumor progression. Mod Pathol 23:367–375, 2010.CrossRefPubMedCentralPubMed
14.
go back to reference Stilling G, Sun Z, Zhang S, Jin L, Righi A, Kovacs G, et al. MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine 38:67–75, 2010.CrossRefPubMed Stilling G, Sun Z, Zhang S, Jin L, Righi A, Kovacs G, et al. MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine 38:67–75, 2010.CrossRefPubMed
15.
go back to reference Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, Asioli S, Chen H, Lloyd RV. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol 26:54–61, 2013.CrossRefPubMedCentralPubMed Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, Asioli S, Chen H, Lloyd RV. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol 26:54–61, 2013.CrossRefPubMedCentralPubMed
16.
go back to reference Nielsen BS, Jorgensen S, Fog JU, Sokilde R, Christensen IJ, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 28: 27–38, 2011.CrossRefPubMedCentralPubMed Nielsen BS, Jorgensen S, Fog JU, Sokilde R, Christensen IJ, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 28: 27–38, 2011.CrossRefPubMedCentralPubMed
17.
go back to reference Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, et al. MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One 9:e88393. 2014.CrossRefPubMedCentralPubMed Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, et al. MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One 9:e88393. 2014.CrossRefPubMedCentralPubMed
18.
go back to reference Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67: 11612–11620, 2007.CrossRefPubMed Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67: 11612–11620, 2007.CrossRefPubMed
19.
go back to reference Swierniak M, Wojcicka A, Czetwertynska M, Stachlewska E, Maciag M, Wiechno W, et al In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma. J Clin Endocrinol Metab 98:E1401–1409, 2013CrossRefPubMed Swierniak M, Wojcicka A, Czetwertynska M, Stachlewska E, Maciag M, Wiechno W, et al In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma. J Clin Endocrinol Metab 98:E1401–1409, 2013CrossRefPubMed
20.
go back to reference Zhang J, Liu Y, Liu Z, Wang XM, Yin DT, Zheng LL, et al. Differential expression profiling and functional analysis of microRNAs through stage I-III papillary thyroid carcinoma. Int J Med Sci. 10:585–592, 2013.CrossRefPubMedCentralPubMed Zhang J, Liu Y, Liu Z, Wang XM, Yin DT, Zheng LL, et al. Differential expression profiling and functional analysis of microRNAs through stage I-III papillary thyroid carcinoma. Int J Med Sci. 10:585–592, 2013.CrossRefPubMedCentralPubMed
21.
go back to reference Pallante P, Visone R, Croce CM, Fusco A. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr Relat Cancer 17: F91–104, 2010.CrossRefPubMed Pallante P, Visone R, Croce CM, Fusco A. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocr Relat Cancer 17: F91–104, 2010.CrossRefPubMed
22.
go back to reference Li Y, Wang Y, Yu L, Sun C, Cheng D, Yu S, et al. miR-146b-5p inhibits glioma migration and invasion by targeting MMP16. Cancer Lett 339:260–9, 2013.CrossRefPubMed Li Y, Wang Y, Yu L, Sun C, Cheng D, Yu S, et al. miR-146b-5p inhibits glioma migration and invasion by targeting MMP16. Cancer Lett 339:260–9, 2013.CrossRefPubMed
23.
go back to reference Wu PY, Zhang XD, Zhu J, Guo XY, Wang JF. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone. Hum Pathol 45:1664–1673, 2014.CrossRefPubMed Wu PY, Zhang XD, Zhu J, Guo XY, Wang JF. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone. Hum Pathol 45:1664–1673, 2014.CrossRefPubMed
24.
go back to reference Patnaik SK, Kannisto E, Mallick R, Yendamuri S. Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells. PLoS One 6(7):e22379, 2011.CrossRefPubMedCentralPubMed Patnaik SK, Kannisto E, Mallick R, Yendamuri S. Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells. PLoS One 6(7):e22379, 2011.CrossRefPubMedCentralPubMed
25.
go back to reference Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. Garcia AI1. EMBO Mol Med. 5:279–284, 2011. Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. Garcia AI1. EMBO Mol Med. 5:279–284, 2011.
26.
go back to reference Geraldo MV, Yamashita AS, Kimura ET. MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer. Oncogene 31:1910–1922, 2011.CrossRefPubMed Geraldo MV, Yamashita AS, Kimura ET. MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer. Oncogene 31:1910–1922, 2011.CrossRefPubMed
27.
go back to reference Zhang J, Yang Y, Liu Y, Fan Y, Liu Z, Wang X, et al MicroRNA-21 regulates biological behaviors in papillary thyroid carcinoma by targeting programmed cell death 4. J Surg Res 189:68–74, 2014.CrossRefPubMed Zhang J, Yang Y, Liu Y, Fan Y, Liu Z, Wang X, et al MicroRNA-21 regulates biological behaviors in papillary thyroid carcinoma by targeting programmed cell death 4. J Surg Res 189:68–74, 2014.CrossRefPubMed
28.
go back to reference Mitomo S, Maesawa C, Ogasawara S, Iwaya T, Shibazaki M, Yashima-Abo A, Izutsu N, et al. Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci 99: 280–286, 2008.CrossRefPubMed Mitomo S, Maesawa C, Ogasawara S, Iwaya T, Shibazaki M, Yashima-Abo A, Izutsu N, et al. Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci 99: 280–286, 2008.CrossRefPubMed
29.
go back to reference Jazdzewski K, Boguslawska J, Jendrzejewski J, Liyanarachchi S, Pachucki J, Wardyn KA, et al. Thyroid hormone receptor {beta}(THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab 96:E546–53, 2010.CrossRefPubMedCentralPubMed Jazdzewski K, Boguslawska J, Jendrzejewski J, Liyanarachchi S, Pachucki J, Wardyn KA, et al. Thyroid hormone receptor {beta}(THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab 96:E546–53, 2010.CrossRefPubMedCentralPubMed
30.
go back to reference Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159: 676–690, 2014.CrossRef Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159: 676–690, 2014.CrossRef
31.
go back to reference Hardin H, Guo Z, Shan W, Montemayor-Garcia C, Asioli S, Yu X-M, et al. The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol 184:2342–2354, 2014CrossRefPubMed Hardin H, Guo Z, Shan W, Montemayor-Garcia C, Asioli S, Yu X-M, et al. The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol 184:2342–2354, 2014CrossRefPubMed
32.
go back to reference Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, et al. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma and follicular adenoma. Endocrine Pathol 17: 213–224, 2006.CrossRef Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, et al. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma and follicular adenoma. Endocrine Pathol 17: 213–224, 2006.CrossRef
Metadata
Title
In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications
Authors
Zhenying Guo
Heather Hardin
Celina Montemayor-Garcia
Sofia Asioli
Alberto Righi
Francesca Maletta
Anna Sapino
Ricardo V. Lloyd
Publication date
01-05-2015
Publisher
Springer US
Published in
Endocrine Pathology / Issue 2/2015
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-015-9363-x

Other articles of this Issue 2/2015

Endocrine Pathology 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine